Ziftomenib and Lenacapavir Oral: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Lenacapavir Oral
Ziftomenib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased ziftomenib exposure and an increased risk of ziftomenib-related adverse reactions
Interaction Deep Dive
Concomitant use of ziftomenib with strong or moderate CYP3A4 inhibitors increases ziftomenib exposure, which may increase the risk of adverse reactions such as QT interval prolongation. Monitor patients more frequently for ziftomenib-associated adverse reactions1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism of ziftomenib
Literature reports
1 report — tap to read
a) In drug interaction studies, itraconazole, voriconazole, and posaconazole (strong CYP3A4 inhibitors) are estimated to increase ziftomenib AUC by up to 3-fold and Cmax by up to 2-fold. Erythromycin, fluconazole, and isavuconazole (moderate CYP3A4 inhibitors) are estimated to increase ziftomenib AUC by up to 2-fold and Cmax by up to 2-fold 1.
Common questions
Can I take Ziftomenib and Lenacapavir Oral together?
Increased ziftomenib exposure and an increased risk of ziftomenib-related adverse reactions Always confirm with your pharmacist or prescriber before making any change.
How serious is the Ziftomenib and Lenacapavir Oral interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Ziftomenib or Lenacapavir Oral need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: KOMZIFTI™ oral capsules, ziftomenib oral capsules. Kura Oncology, Inc (per manufacturer), San Diego, CA, 2025. DailyMed
Keep reading about Lenacapavir Oral
Keep reading about Ziftomenib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist